



Implanet's IPO on NYSE Euronext in Paris is a resounding success

- Over €14 million raised
- Global demand of €31.5 million, oversubscribed 2.3 times
 - Price set at €7.20 per share
- Immediate exercise of the full over-allotment option for €1.8 million

Paris, 19 November 2013 – IMPLANET, a medical technology company specializing in vertebral and knee-surgery implants, today announces the success of its Initial Public Offering with a view to listing the Company's shares on compartment C of the NYSE Euronext regulated market in Paris, raising €14.1 million.

The placement was a resounding success amongst French and international institutional investors, as well as individual investors.

Given the high level of demand (€31.5 million, including €17.6 million within the framework of the Global Placement and €13.9 million within the framework of the Open Price Offer), the Company's Board of Directors met on 19 November 2013 and decided to fully exercise the extension clause and noted the full exercise of the over-allotment option. It also chose to set the price at €7.20 per share. Altogether, a total of 1,959,259 shares were issued, enabling €14.1 million to be raised (issue premium included). The Company's total market capitalization thus stands at €39 million.

A liquidity contract signed with ODDO & Cie will be implemented as soon as trading begins on 25 November 2013.

Settlement-delivery of the shares issued within the framework of the Open Price Offer and the Global Placement will take place on 22 November 2013 and the Company's shares will be traded from 25 November 2013. These shares will be listed on the NYSE Euronext in Paris with ISIN code **FR0010458729** and ticker **IMPL**.

Ludovic Lastennet, CEO and Co-founder of IMPLANET comments: *"On behalf of the team, I am today delighted to be able to announce the resounding success of IMPLANET's Initial Public Offering on the NYSE Euronext market in Paris, which represents a major milestone in the Company's development. I would like to thank our historical shareholders and all those who have just come onboard to make JAZZ a global success. This success is also that of all of our staff who innovate every day to help improve patients' health."*

OFFERING DETAILS

Offering price

- The price of the Open Price Offer and the Global Placement has been set at €7.20 per share.
- This price gives IMPLANET a post-issue market capitalization of approximately €39 million.

Size and gross proceeds of the offering

- 1,959,259 new shares were issued within the framework of the offering.
- The gross proceeds of this issue total approximately €14.1 million.

Allocation of the Offering

- Global Placement: 1,681,259 new shares allocated to institutional investors (corresponding to approximately €12.1 million and 86% of the total number of shares allocated).
- Open Price Offer (OPO): 278,000 new shares allocated to the general public (corresponding to approximately €2.0 million and 14% of the total number of shares allocated).
- Within the framework of the OPO, A1 orders will be 22% satisfied.

Schedule

- Settlement-delivery is planned for 22 November 2013.
- Trading on the NYSE Euronext market in Paris will begin on 25 November 2013.

Financial intermediaries and advisors



ODDO & CIE
Joint Lead Manager and Bookrunner



DSF MARKETS
Joint Lead Manager



Advisor

Availability of the prospectus

Copies of the prospectus that obtained the AMF visa on November 5th 2013 under reference n° 13-586 (the “**Prospectus**”), consisting of the *Document de base* filed on 1 October 2013 under reference n° I.13-045 (the “**Document de Base**”) and a *note d’opération* (including a summary of the prospectus), are available free of charge on request from IMPLANET (Technopole Bordeaux Montesquieu, Allée François Magendie, 33650 Martillac, France). The Prospectus can also be found on the Implanet (www.implanet.com) and AMF (www.amf-france.org) websites.

Risk factors

IMPLANET would like to draw your attention to Chapter 4 (Risk factors) of the *document de base* registered with the AMF French stock market authorities and more particularly on the risk factor “liquidity risk – *Risque de liquidité*” presented on the section 4.7.4 of the document, as well as Section 2 (Risk factors relating to the Offering) of the *note d’opération*. The occurrence of all or any of these risks would be likely to have a negative effect on the Company's activities, results, financial situation and outlook.

This document may not be published, distributed or circulated, either directly or indirectly, in the United States, Canada, Australia, Italy or Japan.

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. IMPLANET's proven orthopedic platform, based on perfectly controlling the traceability of its products, gives the Company the proven ability to enhance this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory approval from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 33 staff and recorded 2012 sales of €6.6 million.

For further information, please visit www.implanet.com

Contacts

IMPLANET

Ludovic Lastennet
Chief Executive Officer
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com

NewCap.

Investor Relations & Financial Communication
Florent Alba / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr

Disclaimer

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for IMPLANET shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

In particular:

This press release does not constitute an offer to sell or any solicitation to purchase or subscribe for securities in the United States. The shares, or any other securities of IMPLANET, may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended, or exempt from registration. The shares of IMPLANET have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and IMPLANET does not intend to make any public offer of its shares in the United States.

This press release is solely an advertisement and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, in particular, by Directive 2010/73/EC of the European Parliament and the Council of November 24th, 2010 and as implemented in each member State of the European Economic Area (the "Prospectus Directive"). With respect to the member States of the European Economic Area which have transposed the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to in this press release requiring a publication by IMPLANET of a prospectus in any member State, other than France. As a result, the shares of IMPLANET may not be offered or will not be offered in any member State other than France, except, pursuant to the exemptions described in article 3(2) of the Prospectus Directive, if they have been implemented by the relevant member State or in any other circumstances not requiring IMPLANET to publish a prospectus as provided under article 3(2) of the Prospectus Directive and/or regulations applicable in such member State.

This press release is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial

This document may not be published, distributed or circulated, either directly or indirectly, in the United States, Canada, Australia, Italy or Japan.

Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The prospectus registered with the Autorité des Marchés Financiers contains forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in the prospectus, and to the development of economic conditions, the financial markets and the markets in which IMPLANET operates.

ODDO & Cie, acting as stabilising agent, or any institution acting on its behalf may, during a period of 30 days following the date on which the Offering Price is determined, i.e., according to the indicative timetable, from 19 November to 19 December 2013, effect transactions with a view to maintaining the market price of the IMPLANET shares in a manner consistent with applicable laws and regulations and, in particular, EU Commission regulation number 2273/03 of 22 December 2003. These activities are intended to support the market price of the IMPLANET shares and may affect the share price.